Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target. (2019)
Attributed to:
Bitopic protein kinase inhibition - a new paradigm in drug discovery
funded by
EPSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1126/science.aau1682
PubMed Identifier: 31467193
Publication URI: http://europepmc.org/abstract/MED/31467193
Type: Journal Article/Review
Volume: 365
Parent Publication: Science (New York, N.Y.)
Issue: 6456
ISSN: 0036-8075